Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002874 (
aplastic anemia
)
5,905
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Large granular lymphocyte leukemia (LGL) is often associated with immune cytopenias and can cooccur in the context of
aplastic anemia
(AA) and myelodysplastic syndromes (MDS). We took advantage of the recent description of
signal transducer and activator of transcription 3
(
STAT3
) mutations in LGL clonal expansions to test, using sensitive methods, for the presence of these mutations in a large cohort of 367 MDS and 140 AA cases.
STAT3
clones can be found not only in known LGL concomitant cases, but in a small proportion of unsuspected ones (7% AA and 2.5% MDS). In
STAT3
-mutated AA patients, an interesting trend toward better responses of immunosuppressive therapy and an association with the presence of human leukocyte antigen-DR15 were found. MDSs harboring a
STAT3
mutant clone showed a lower degree of bone marrow cellularity and a higher frequency of developing chromosome 7 abnormalities.
STAT3
-mutant LGL clones may facilitate a persistently dysregulated autoimmune activation, responsible for the primary induction of bone marrow failure in a subset of AA and MDS patients.
...
PMID:STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. 2409 24
Germline loss-of-function mutations in the transcription factor
signal transducer and activator of transcription 3
(
STAT3
) cause immunodeficiency, whereas somatic gain-of-function mutations in
STAT3
are associated with large granular lymphocytic leukemic, myelodysplastic syndrome, and
aplastic anemia
. Recently, germline mutations in
STAT3
have also been associated with autoimmune disease. Here, we report on 13 individuals from 10 families with lymphoproliferation and early-onset solid-organ autoimmunity associated with 9 different germline heterozygous mutations in
STAT3
. Patients exhibited a variety of clinical features, with most having lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity (lung, gastrointestinal, hepatic, and/or endocrine dysfunction), infections, and short stature. Functional analyses demonstrate that these mutations confer a gain-of-function in
STAT3
leading to secondary defects in STAT5 and STAT1 phosphorylation and the regulatory T-cell compartment. Treatment targeting a cytokine pathway that signals through
STAT3
led to clinical improvement in 1 patient, suggesting a potential therapeutic option for such patients. These results suggest that there is a broad range of autoimmunity caused by germline
STAT3
gain-of-function mutations, and that hematologic autoimmunity is a major component of this newly described disorder. Some patients for this study were enrolled in a trial registered at www.clinicaltrials.gov as #NCT00001350.
...
PMID:Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. 2561 33